Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure

AIDS Research and Human Retroviruses

Volumn 24, Issue 2, 2008, Pages 149-154

  Di Giambenedetto, S ^a   Colafigli, M ^a   Pinnetti, C ^a   Bacarelli, A ^a   Cingolani, A ^a   Tamburrini, E ^a   Cauda, R ^a   De Luca, A ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS RESISTANCE;

ADULT; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION, MISSENSE; RNA, VIRAL; VIRAL LOAD;

EID: 39549103445     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0070     Document Type: Article

References (26)

1. Palella FJ, Delankey KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
2. Hogg RS, O'Shaughnessy MV, Gataric N, et al.: Decline in deaths from AIDS due to new antiretrovirals [letter]. Lancet 1997;349:1294.
3. Jain MK, Skiest DJ, Cloud JW, et al.: Changes in mortality related to human immunodeficiency infection: Comparative analysis of inpatient deaths in 1995 and in 1999-2000. Clin Infect Dis 2003;36:1030-1038.
4. Durant J, Clevenbergh P, Halfon P, et al.: Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial. Lancet 1999;353:2195-2199.
5. Durant J, Clevenbergh P, Halfon P, et al.: Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt study: Week 48 follow-up. Antiviral Ther 2000;5:65-70.
6. Baxter JD, Mayers DL, Wentworth DN, et al.: A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 2000;14:F83-93.
7. Tural C, Ruiz L, Holtzer C, et al.: Clinical utility of HIV-1 genotyping and expert advice: The Havana trial. AIDS 2002;16:727-736.
8. Meynard JL, Vray M, Morand-Joubert L, et al.: Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: A randomized trial. AIDS 2002;16:727-736.
9. Cingolani A, Antinori A, Rizzo MG, et al.: Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: A randomized study (ARGENTA). AIDS 2002;16:369-379.
10. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents, Panel on Clinical Practices for Treatment of HIV infection convened by the Department of Health and Human Services (DHHS), http://AIDSinfo.nih.gov, updated October 10, 2006.
11. De Luca A, Cingolani A, Di Giambenedetto S, et al.: Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis 2003;187:1934-1943.
12. De Luca A, Cozzi-Lepri A, Perno CF, et al.: Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systems. Antiviral Ther 2004;9:743-752.
13. Van Laethem K, De Luca A, Antinori A, et al.: A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1 infected patients. Antiviral Ther 2002;7:123-129.
14. Torti C, Quiros-Roldan E, Regazzi M, et al.: A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: The Resistance and Dosage Adapted Regimens (RADAR) study. Clin Infect Dis 2005;40:1828-1836.
15. Lucas GM, Gallant JE, and Moore RD: Relationship between drugresistance and HIV-1 disease progression or death in patients undergoing resistance testing. AIDS 2004;18:1539-1548.
16. Recsky MA, Brumme ZL, Chan KJ, et al.: Antiretroviral resistance among HIV-infected people who have died in British Columbia, in the era of modern antiretroviral therapy. J Infect Dis 2004;190:285-292.
17. Zaccarelli M, Tozzi V, Lorenzini P, et al.: Multiple drug classwide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS 2005;19:1081-1089.
18. Johnson VA, Brun-Vezinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med 2004;12:119-124.
19. Cooper J: 24-week RESIST Study analyses: The efficacy of tipranavir/ritonavir (TPV/r) is superior to lopinavir/ritonavir (LPV/r) and TPV/r treatment response is enhanced by inclusion of genotypically active antiretrovirals in the optimized background regimen (OBR). 12th Conference of Retroviruses and Opportunistic Infections 2005, Abstract 560.
20. De Luca A, Di Giambenedetto S, Cingolani A, et al.: Three-year clinical outcomes of resistance genotyping and expert advice: Extended follow-up of the Argenta trial. Antiviral Ther 2006;11:321-327.
21. Hogg RS, Bangsberg D, Alexander C, et al.: Drug resistance is associated with an increased risk of death in patients first starting HAART. Programme and Abstract of the 12th CROI, Boston, February 2005, Abstract 121.
22. Miller MD, Margot N, Lu B, et al.: Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 2004;189:837-846.
23. Delgado J and Shulman N: NNRTI hypersusceptibility. AIDS Read 2005;15:28-30.
24. De Luca A, Di Giambenedetto S, Romano L, et al.: Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy. J Infect Dis 2006;193:1219-1222.
25. Cozzi-Lepri A, Ruiz L, Loveday C, et al.: Thymidine analogue mutation profiles: Factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antiviral Ther 2005;10:791-802.
26. Brun-Vezinet F, Descamps D, Ruffault A, et al.: Clinically relevant interpretation of genotype for resistance to abacavir. AIDS 2003;17:1795-1802.